首页> 美国卫生研究院文献>Clinical and Molecular Hepatology >Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C
【2h】

Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C

机译:聚乙二醇干扰素-α2b和利巴韦林联合治疗慢性丙型肝炎期间发生Vogt-Koyanagi-Harada病

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Vogt-Koyanagi-Harada (VKH) disease is a multisystem syndrome characterized by ocular (uveitis and retinal detachment), neurological (headache, tinnitus, and meningitis), and integumentary (vitiligo, alopecia, and poliosis) involvement. Although the pathogenesis of VKH disease is not well understood, an autoimmune T-cell response to a melanocyte-associated antigen is considered to be a cause of VKH disease. The complex immunological response to interferon and ribavirin may induce or exacerbate the autoimmune condition; however, VKH disease is a very rare complication associated with interferon therapy in chronic hepatitis C. We report a case of VKH disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C.
机译:Vogt-Koyanagi-Harada(VKH)疾病是一种多系统综合征,其特征是眼部(葡萄膜炎和视网膜脱离),神经系统(头痛,耳鸣和脑膜炎)和皮肤外(玻璃体,脱发和小儿麻痹)受累。尽管对VKH疾病的发病机理还没有很好的了解,但是对黑素细胞相关抗原的自身免疫性T细胞应答被认为是VKH疾病的原因。对干扰素和利巴韦林的复杂免疫反应可能诱发或加重自身免疫病。然而,VKH疾病是与慢性丙型肝炎的干扰素治疗相关的非常罕见的并发症。我们报道了一例在聚乙二醇化干扰素-α2b和利巴韦林联合治疗慢性丙型肝炎期间发生的VKH疾病病例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号